Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KU4M
|
|||
| Former ID |
DCL000161
|
|||
| Drug Name |
MB07803
|
|||
| Synonyms |
MB-07803; 882757-24-6; UNII-GG81XF45C2; MB 07803; GG81XF45C2; SCHEMBL14255484; DTXSID90236932; ACT04837; SB17400; DB05053; HY-16309; CS-0006389; Alanine, N,N'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methyl-, diethyl ester; n,n'-((5-(2-amino-5-(2,2-dimethyl-1-oxopropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(2-methylalanine) diethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1], [2] | |
| Company |
Metabasis Therape
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H37N4O7PS
|
|||
| Canonical SMILES |
CCOC(=O)C(C)(C)NP(=O)(C1=CC=C(O1)C2=C(SC(=N2)N)C(=O)C(C)(C)C)NC(C)(C)C(=O)OCC
|
|||
| InChI |
1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)
|
|||
| InChIKey |
CTKZZUXRWBCFEI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 882757-24-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fructose-1,6-bisphosphatase (FBP) | Target Info | Modulator | [3] |
| BioCyc | Gluconeogenesis | |||
| KEGG Pathway | Glycolysis / Gluconeogenesis | |||
| Pentose phosphate pathway | ||||
| Fructose and mannose metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| AMPK signaling pathway | ||||
| Insulin signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Pathwhiz Pathway | Fructose and Mannose Degradation | |||
| Pentose Phosphate Pathway | ||||
| Gluconeogenesis | ||||
| Reactome | Gluconeogenesis | |||
| WikiPathways | Glycolysis and Gluconeogenesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00458016) Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.